Group items tagged

Companion animals are domesticated or domestic-bred animals whose physical, emotional, behavioral and social needs can be readily met as companions in the home or a close daily relationship with humans. Companion animal health market mainly comprises of medicines, medicinal feed additives, and vaccines and caters to both foods producing and companion animals. China Companion Animal Health Market was worth US$ XX Million in 2019 and is expected to reach US$ XX Million by 2026, at a CAGR of XX% during the forecast period 2019-2026. Download Free Sample Report: https://www.datamintelligence.com/download-sample/china-companion-animal-health-market View Full Report Sample: https://www.datamintelligence.com/research-report/china-companion-animal-health-market

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o